➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
McKesson
Mallinckrodt
Boehringer Ingelheim
Harvard Business School

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Patent: 10,179,811

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,179,811
Title:Methods of treating Crohn\'s disease or ulcerative colitis using an induction dosing regimen comprising anti-TNF-alpha antibody
Abstract: The invention relates to a multiple-variable dose method for treating a disorder in which TNF.alpha. activity is detrimental, comprising administering to a subject in need thereof a first induction dose of an anti-TNF.alpha. antibody which ranges from 161 to 320 mg such that a threshold level of TNF.alpha. inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNF.alpha. inhibitor within a treatment phase, such that treatment occurs.
Inventor(s): Moodie; Rachel (Hofstetten, CH), Hyland; Elizabeth (Neuchatel, CH)
Assignee: Fresenius Kabi Deutschland GmbH (Bad Homburg, DE)
Application Number:15/564,677
Patent Claims:see list of patent claims

Details for Patent 10,179,811

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial Fresenius Kabi Deutschland GmbH (Bad Homburg, DE) 2035-04-10 RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial Fresenius Kabi Deutschland GmbH (Bad Homburg, DE) 2035-04-10 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Moodys
Johnson and Johnson
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.